To Explore the Safety and Efficacy of Hypervision Proton Surgery for Early-stage Non-small Cell Lung Cancer

This study was a single-center, single-arm clinical study to evaluate the safety and efficacy of hypervision proton surgery with single large fractionated doses (34GyE and 39GyE) in the treatment of early peripheral NSCLC.

Trial Details

NCT ID
NCT07195084
Phase
NA
Sponsor
Anhui Provincial Cancer Hospital
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Hypervision proton surgery
Locations (sample)
  • Hefei, Anhui, China|31.86389,117.28083

Key Eligibility Criteria

  • The patient must be at least 18 years old
  • Karnofsky Performance Status \> 80
  • NSCLC confirmed by cytology or histology; for subjects who cannot safely obtain pathological evidence due to factors such as tumor lesion location,…
  • Early-stage tumors are defined as T1 (≤3cm) N0M0 based on enhanced computed tomography (CT) and positron emission tomography (PET)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →